







Obagi Tretinoin Gel 0.05% is a topical prescription retinoid indicated for the treatment of acne vulgaris. Each gram contains 0.5 mg of tretinoin, equivalent to a concentration of 0.05%, in a topical gel formulation.
Tretinoin is also known as all-trans retinoic acid. It is an active metabolite of vitamin A and is distinct from cosmetic retinol products. This Obagi formulation is supplied as a 20 g tube of translucent to opaque, pale-yellow gel.
Obagi Tretinoin Gel 0.05% is indicated for the topical treatment of acne vulgaris, including skin affected by comedones such as blackheads and whiteheads, and inflammatory acne lesions.
The precise role of tretinoin within an acne treatment plan depends on the type and severity of acne, the condition of the skin, previous treatment and the other products or medicines being used.
Tretinoin belongs to the retinoid class of medicines. It interacts with retinoic acid receptors involved in gene expression and the growth and differentiation of epithelial cells.
Its complete mechanism of action in acne has not been fully established. Current evidence indicates that topical tretinoin reduces the cohesiveness of cells within the follicle, helping to reduce the formation of microcomedones. It also increases the turnover of follicular epithelial cells, supporting the clearance of existing comedones.
The concentration of 0.05% means that each gram of gel contains 0.5 mg of tretinoin. It does not mean that the product contains 0.5% tretinoin.
The gel and cream versions of tretinoin use different formulation bases. Although a 0.05% gel and a 0.05% cream contain the same concentration of active ingredient, their vehicles, application characteristics and tolerability may differ. They should not be regarded as interchangeable solely because the stated concentration is the same.
This specific Obagi gel contains fish collagen hydrolysates. Anyone with a known fish allergy or sensitivity should disclose this during their consultation.
Use Obagi Tretinoin Gel exactly as directed by your prescriber. The manufacturer’s directions describe once-daily application before bedtime, although your individual instructions may differ.
Using a larger quantity or applying the gel more frequently will not produce faster or better results and may increase irritation.
Response to topical tretinoin develops progressively and varies between individuals. Clinical studies for this formulation assessed treatment over 12 weeks, but this does not establish a guaranteed timescale for an individual patient.
Dryness, redness, peeling, scaling or a burning sensation can occur, particularly during the early part of treatment. These effects do not indicate that a larger quantity should be applied. Persistent, severe or otherwise concerning irritation should be discussed with the prescriber.
A simple routine can help limit avoidable irritation while using tretinoin. The treated area should be cleansed gently without repeated washing or scrubbing. A suitable non-comedogenic moisturiser may be used where required.
Exercise caution with medicated or abrasive cleansers, scrubs, astringents, strongly drying products and topical acne preparations containing ingredients such as benzoyl peroxide, salicylic acid, sulphur or resorcinol. Other retinoids and exfoliating acids may also increase irritation. Their use should be discussed with the prescriber rather than added independently.
Cosmetics may be used, but they should be removed and the skin cleansed before the gel is applied.
Minimise unprotected exposure to sunlight, sunlamps and tanning beds while using tretinoin. Use an appropriate broad-spectrum sunscreen and protective clothing when exposure cannot be avoided.
Do not apply the gel to sunburned skin. Wind and cold weather may also increase dryness or irritation in treated areas.
The most commonly reported reactions associated with this formulation are local skin effects at or around the application area. These may include:
Temporary increases or decreases in skin pigmentation have also been reported following repeated application of topical tretinoin. Seek medical advice if a reaction is severe, persistent or suggestive of sensitivity, including hives or marked itching.
The prescribing information describes two 12-week, prospective, multicentre, randomised controlled studies of this 0.05% tretinoin gel in mild-to-moderate acne vulgaris. Across the two studies, 674 participants received tretinoin gel and 487 received its vehicle gel.
The assessed outcomes included inflammatory, non-inflammatory and total facial lesion counts, together with global acne severity. The studies reported greater average reductions in lesion counts in the tretinoin groups than in the corresponding vehicle groups. They also recorded local adverse reactions, most commonly dryness, peeling or flaking, burning sensation and redness.
Clinical-study findings describe results across groups of participants and cannot predict the response or tolerability of an individual patient.
Active ingredient: Tretinoin 0.05% w/w.
Other ingredients: Benzyl alcohol, butylparaben, butylated hydroxytoluene, carbomer homopolymer Type C, ethylparaben, fish collagen hydrolysates, glycerin, isobutylparaben, methylparaben, octoxynol 9, phenoxyethanol, propylparaben, purified water, sodium hyaluronate and trolamine.
Store at room temperature between 20°C and 25°C. Protect from freezing and keep the tube out of the reach of children.
It is a prescription topical retinoid containing 0.05% tretinoin. Its labelled indication is the topical treatment of acne vulgaris.
No. Tretinoin is all-trans retinoic acid and acts directly as a retinoid medicine. Retinol is a different vitamin A derivative commonly used in cosmetic skincare and must undergo conversion within the skin. The percentages used for tretinoin and retinol are not directly comparable.
No. This product contains tretinoin at 0.05% w/w, equivalent to 0.5 mg per gram of gel. The decimal point is clinically important.
Both can contain tretinoin, but their formulation bases are different. This can affect texture, application and tolerability. A gel is not automatically more suitable than a cream, and the appropriate formulation should be selected according to the individual’s skin and treatment plan.
Yes. The stated indication for this particular formulation is the topical treatment of acne vulgaris.
This product’s labelled indication is acne vulgaris. Tretinoin may be prescribed in other clinical contexts, but any use outside the stated indication requires an individual medical decision and should not be inferred from cosmetic retinol products or general skincare claims.
Apply only the amount needed to form a thin layer over the complete affected area, following the directions supplied by the prescriber. Applying more will not improve efficacy and may increase irritation.
A suitable non-comedogenic moisturiser may be used to help manage dryness. The timing and choice of products should be consistent with the individual treatment instructions.
These and other topical acne treatments can increase dryness or irritation when combined with tretinoin. They should only be incorporated in the manner advised by the prescriber.
The Obagi 0.05% gel formulation contains fish collagen hydrolysates. Anyone with a known fish allergy or sensitivity should disclose this before treatment and seek advice if itching or hives develop.
Response varies between individuals. The clinical studies for this formulation assessed outcomes over 12 weeks, but this is not a guaranteed treatment timescale. Use should be reviewed according to the individual treatment plan.